Altimmune Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
ALT$1.94-8.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
6. Accrued Expenses and Other Current Liabilities
- Accrued Expenses and Other Current Liabilities
Accrued expense and other current liabilities consist of the following (in thousands):
| · · · · · · | ||||
|---|---|---|---|---|
| · · December 31, | ||||
| | | 2024 | | 2023 |
| Accrued professional services | $401 | $293 | ||
| Accrued payroll and employee benefits | | 3,079 | | 3,315 |
| Accrued research and development | | 6,443 | | 5,845 |
| Lease obligation, current portion (see Note 5) | | 279 | | 496 |
| Accrued interest and other | | 55 | | 124 |
| Total accrued expenses and other current liabilities | | $10,257 | | $10,073 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.